Quantitative assessment of the association between XRCC3 C18607T polymorphism and glioma risk

XRCC3 has an important function in the DNA double-strand break, and XRCC3 C18607T polymorphism is a common polymorphism at exon 7 of the XRCC3 gene. Published data on the association between XRCC3 C18607T polymorphism and glioma risk were inconclusive. Electronic databases of PubMed, and Embase were searched for studies assessing the association between XRCC3 C18607T polymorphism and glioma risk. Pooled odds ratio (OR) and 95 % confidence interval (95 % CI) were calculated to estimate the association. Ten studies with five studies from Caucasians and five studies from Asians were included, including 9,369 subjects. Meta-analysis of total included studies showed that XRCC3 C18607T polymorphism was associated with increased risk of glioma (T vs. C: OR = 1.14, 95 % CI 1.02–1.28, P = 0.02; TT vs. CC: OR = 1.37, 95 % CI 1.03–1.83, P = 0.03; TT vs. CC/CT: OR = 1.31, 95 % CI 1.00–1.71, P = 0.05; TT/CT vs. CC: OR = 1.12, 95 % CI 1.02–1.22, P = 0.02). Meta-analysis of the five studies from Asians showed that XRCC3 C18607T polymorphism was associated with increased risk of glioma (T vs. C: OR = 1.22, 95% CI 1.09–1.36, P < 0.01; TT vs. CC: OR = 1.89, 95 % CI 1.38–2.57, P < 0.01; TT vs. CC/CT: OR = 1.78, 95 % CI 1.31–2.40, P < 0.01; TT/CT vs. CC: OR = 1.19, 95 % CI 1.04–1.36, P = 0.01). Meta-analysis of the five studies from Caucasians didn’t find the association. In conclusion, the finding from the meta-analysis provides strong evidence for the association between XRCC3 C18607T polymorphism and glioma risk.